{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T21:23:39Z","timestamp":1750973019964,"version":"3.41.0"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>As health care providers, we play a crucial role in the assessment of a patient\u2019s risk for hereditary breast cancer syndromes. The panorama of genetic assessment and testing has evolved dramatically since the identification of the<jats:italic toggle=\"yes\">BRCA<\/jats:italic>genes. Next-generation sequencing technology has facilitated the development of multigene panels, but 1 consequence has been an increased identification of pathogenic variants at odds with a family history as well as variants of uncertain significance for which treatment guidelines are not defined. Progress in this field requires close collaboration between patients and clinicians with a thorough understanding in cancer genetics.<\/jats:p>","DOI":"10.1097\/grf.0000000000000236","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T14:29:39Z","timestamp":1475764179000},"page":"673-687","source":"Crossref","is-referenced-by-count":2,"title":["Breast Cancer: Genetics and Risk Assessment"],"prefix":"10.1097","volume":"59","author":[{"given":"TREVOR","family":"TEJADA-BERG\u00c9S","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1073\/pnas.85.9.3044","article-title":"Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families","volume":"85","author":"Newman","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0140-6736(91)90076-2","article-title":"Familial breast ovarian cancer locus on chromosome 17q12-q23","volume":"338","author":"Narod","year":"1991","journal-title":"Lancet"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1126\/science.8091231","article-title":"Localization of a breast cancer susceptibility gene, BRCA2, to chromosome13q12-13","volume":"265","author":"Wooster","year":"1994","journal-title":"Science"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/jmg.40.11.807","article-title":"Evaluation of breast cancer risk assessment packages in the Family History Evaluation and Screening Programme","volume":"40","author":"Amir","year":"2003","journal-title":"J Med Genet"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5","article-title":"Autosomal dominant inheritance of early onset breast cancer","volume":"73","author":"Claus","year":"1994","journal-title":"Cancer"},{"key":"R8-20230915","first-page":"232","article-title":"Genetic analysis of breast cancer in the cancer and steroid hormone study","volume":"48","author":"Claus","year":"1991","journal-title":"Am J Hum Genet"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00666424","article-title":"The calculation of breast cancer risk for women with a first degree family history of ovarian cancer","volume":"28","author":"Claus","year":"1993","journal-title":"Breast Cancer Res Treat"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/jnci\/88.18.1315","article-title":"Agreement between breast cancer risk estimation methods","volume":"88","author":"McGuigan","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/jnci\/94.11.844","article-title":"Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO","volume":"94","author":"Euhus","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/M13-2747","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann Intern Med"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2007.09.031","article-title":"Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions","volume":"107","author":"Lancaster","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","article-title":"A breast cancer prediction model incorporating familial and personal risk factors","volume":"23","author":"Tyrer","year":"2004","journal-title":"Stat Med"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1086\/301670","article-title":"Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2","volume":"62","author":"Parmigiani","year":"1998","journal-title":"Am J Hum Genet"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6604305","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions","volume":"98","author":"Antoniou","year":"2008","journal-title":"Br J Cancer"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/jmg.2007.056556","article-title":"Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics","volume":"45","author":"Antoniou","year":"2008","journal-title":"J Med Genet"},{"key":"R18-20230915","first-page":"143","article-title":"More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling","volume":"13","author":"Sie","year":"2014","journal-title":"Fam Cancer"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jnci\/djh017","article-title":"Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis","volume":"96","author":"Braithwaite","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.7717\/peerj.8","article-title":"Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing","volume":"1","author":"Francke","year":"2013","journal-title":"PeerJ"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N Engl J Med"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","article-title":"Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment","volume":"32","author":"Kurian","year":"2014","journal-title":"J Clin Oncol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2014.05.028","article-title":"Preoperative genetic testing affects surgical decision making in breast cancer patients","volume":"134","author":"Lokich","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/gim.2015.50","article-title":"Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? Results from a randomized clinical trial","volume":"18","author":"Wevers","year":"2016","journal-title":"Genet Med"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archsurg.138.12.1323","article-title":"Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis","volume":"138","author":"Weitzel","year":"2003","journal-title":"Arch Surg"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1200\/JCO.2004.04.086","article-title":"Impact of BRCA1\/BRCA2 counseling and testing on newly diagnosed breast cancer patients","volume":"22","author":"Schwartz","year":"2004","journal-title":"J Clin Oncol"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2006.09.1900","article-title":"How often do BRCA mutation carriers tell their young children of the family\u2019s risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults","volume":"25","author":"Bradbury","year":"2007","journal-title":"J Clin Oncol"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/gim.2014.40","article-title":"Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients","volume":"16","author":"LaDuca","year":"2014","journal-title":"Genet Med"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/cge.12315","article-title":"A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes","volume":"86","author":"Eggington","year":"2014","journal-title":"Clin Genet"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"R31-20230915","first-page":"6643","article-title":"Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype","volume":"63","author":"Olivier","year":"2003","journal-title":"Cancer Res"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/jmg.2007.051268","article-title":"Germline E-cadherin mutations in familial lobular breast c\u00e1ncer","volume":"44","author":"Masciari","year":"2007","journal-title":"J Med Genet"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/1078-0432.CCR-06-0083","article-title":"Frequency and spectrum of cancers in the Peutz-Jeghers syndrome","volume":"12","author":"Hearle","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13053-016-0049-2","article-title":"PALB2: research reaching to clinical outcomes for women with breast cancer","volume":"14","author":"Southey","year":"2016","journal-title":"Hered Cancer Clin Pract"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/01.GIM.0000151155.36470.FF","article-title":"Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications","volume":"7","author":"McClain","year":"2005","journal-title":"Genet Med"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"issue":"suppl 6","key":"R38-20230915","doi-asserted-by":"crossref","first-page":"vi93","DOI":"10.1093\/annonc\/mdm234","article-title":"Founder mutations in BRCA1 and BRCA2 genes","volume":"18","author":"Ferla","year":"2007","journal-title":"Ann Oncol"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","article-title":"Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"27","author":"Graeser","year":"2009","journal-title":"J Clin Oncol"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"747","DOI":"10.7326\/0003-4819-71-4-747","article-title":"Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?","volume":"71","author":"Li","year":"1969","journal-title":"Ann Intern Med"},{"key":"R41-20230915","first-page":"5358","article-title":"A cancer family syndrome in twenty-four kindreds","volume":"48","author":"Li","year":"1988","journal-title":"Cancer Res"},{"key":"R42-20230915","first-page":"2984","article-title":"Inherited p53 gene mutations in breast cancer","volume":"52","author":"Sidransky","year":"1992","journal-title":"Cancer Res"},{"key":"R43-20230915","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(11)70119-X","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study","volume":"12","author":"Villani","year":"2011","journal-title":"Lancet Oncol"},{"key":"R44-20230915","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2006.11.042","article-title":"Essential role for nuclear PTEN in maintaining chromosomal integrity","volume":"128","author":"Shen","year":"2007","journal-title":"Cell"},{"key":"R45-20230915","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10897-008-9187-7","article-title":"Cowden syndrome: a critical review of the clinical literature","volume":"18","author":"Pilarski","year":"2009","journal-title":"J Genet Couns"},{"key":"R46-20230915","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jmg.2009.074237","article-title":"Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research","volume":"47","author":"Fitzgerald","year":"2010","journal-title":"J Med Genet"},{"key":"R47-20230915","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1053\/gast.2001.29611","article-title":"Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families","volume":"121","author":"Pharoah","year":"2001","journal-title":"Gastroenterology"},{"key":"R48-20230915","doi-asserted-by":"crossref","first-page":"L331","DOI":"10.1042\/BJ20140208","article-title":"Exploring the roles of PALB2 at the crossroads of DNA repair and cancer","volume":"460","author":"Pauty","year":"2014","journal-title":"Biochem J"},{"key":"R49-20230915","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","article-title":"Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2","volume":"22","author":"Xia","year":"2006","journal-title":"Mol Cell"},{"key":"R50-20230915","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/cge.12710","article-title":"Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline","volume":"90","author":"Van Os","year":"2016","journal-title":"Clin Genet"},{"key":"R51-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2014.10.008","article-title":"Beyond BRCA: new hereditary breast cancer susceptibility genes","volume":"41","author":"Economopoulou","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"R52-20230915","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/carcin\/bgq210","article-title":"RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer","volume":"31","author":"Somayajit","year":"2010","journal-title":"Carcinogenesis"},{"key":"R53-20230915","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/RLI.0b013e3181f3fcdf","article-title":"Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk Italian 1 study): final results","volume":"46","author":"Sardanelli","year":"2011","journal-title":"Invest Radiol"},{"key":"R54-20230915","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","article-title":"Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination","volume":"292","author":"Warner","year":"2004","journal-title":"JAMA"},{"key":"R55-20230915","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J Clin Oncol"},{"key":"R56-20230915","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10549-009-0607-7","article-title":"Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition","volume":"119","author":"Obdeijn","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R57-20230915","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R58-20230915","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"key":"R59-20230915","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R60-20230915","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","article-title":"Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group","volume":"356","author":"Narod","year":"2000","journal-title":"Lancet"},{"key":"R61-20230915","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.21536","article-title":"Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update","volume":"118","author":"Gronwald","year":"2006","journal-title":"Int J Cancer"},{"key":"R62-20230915","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-158-8-201304160-00005","article-title":"Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force","volume":"158","author":"Nelson","year":"2013","journal-title":"Ann Intern Med"},{"key":"R63-20230915","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"key":"R64-20230915","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N Engl J Med"},{"key":"R65-20230915","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J Clin Oncol"},{"key":"R66-20230915","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1245\/s10434-013-3230-0","article-title":"Total skin-sparing mastectomy in BRCA mutation carriers","volume":"21","author":"Peled","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R67-20230915","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J Clin Oncol"},{"key":"R68-20230915","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R69-20230915","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"R70-20230915","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"key":"R71-20230915","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-010-0894-z","article-title":"Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy","volume":"121","author":"Pierce","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R72-20230915","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000369592","article-title":"Impact of prophylactic mastectomy in BRCA1\/2 mutation carriers","volume":"9","author":"Rhiem","year":"2014","journal-title":"Breast Care (Basel)"},{"key":"R73-20230915","doi-asserted-by":"crossref","first-page":"g226","DOI":"10.1136\/bmj.g226","article-title":"Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis","volume":"348","author":"Metcalfe","year":"2014","journal-title":"BMJ"},{"key":"R74-20230915","first-page":"287","article-title":"Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers","volume":"93","author":"Van Sprundel","year":"2005","journal-title":"BMJ"},{"key":"R75-20230915","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jama.284.3.319","article-title":"Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy","volume":"284","author":"Frost","year":"2000","journal-title":"JAMA"},{"key":"R76-20230915","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/01.prs.0000217383.99038.f5","article-title":"Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women","volume":"117","author":"Bresser","year":"2006","journal-title":"Plast Reconstr Surg"},{"key":"R77-20230915","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","article-title":"Quality-of-life effects of prophylactic salpingooophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer","volume":"23","author":"Madalinska","year":"2005","journal-title":"J Clin Oncol"},{"key":"R78-20230915","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R79-20230915","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"R80-20230915","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1200\/JCO.2006.06.5888","article-title":"American Society of Clinical Oncology recommendations on fertility preservation in cancer patients","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"R81-20230915","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.fertnstert.2005.03.013","article-title":"Medicine fertility preservation and reproduction in cancer patients","volume":"83","year":"2005","journal-title":"Fertil Steril"},{"key":"R82-20230915","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/(SICI)1097-0142(19990815)86:4<697::AID-CNCR20>3.0.CO;2-J","article-title":"Having children after cancer","volume":"86","author":"Schover","year":"1999","journal-title":"Cancer"},{"key":"R83-20230915","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1200\/JCO.2009.23.0250","article-title":"Physician referral for fertility preservation in oncology patients: a national study of practice behaviors","volume":"27","author":"Quinn","year":"2009","journal-title":"J Clin Oncol"},{"key":"R84-20230915","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10689-007-9171-7","article-title":"Cancer risk reduction and reproductive concerns in female BRCA1\/2 mutation carriers","volume":"7","author":"Staton","year":"2008","journal-title":"Fam Cancer"},{"key":"R85-20230915","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.fertnstert.2008.03.019","article-title":"Attitudes of high-risk women toward preimplantation genetic diagnosis","volume":"91","author":"Quinn","year":"2009","journal-title":"Fertil Steril"},{"key":"R86-20230915","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1200\/JCO.2006.06.6100","article-title":"Cancer genetic testing and assisted reproduction","volume":"24","author":"Offit","year":"2006","journal-title":"J Clin Oncol"},{"key":"R87-20230915","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrclinonc.2010.175","article-title":"The role of BRCA mutation testing in determining breast cancer therapy","volume":"7","author":"Trainer","year":"2010","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003081-201612000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T01:55:25Z","timestamp":1749606925000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003081-201612000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000236","relation":{},"ISSN":["0009-9201"],"issn-type":[{"type":"print","value":"0009-9201"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}